Open access · CC-BY
via OpenAlex
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease
Marco J. Russo, Christina Doriana Orru, Luis Concha‐Marambio, Simone Giaisi, Bradley R. Groveman, Carly M. Farris, Bret Holguin, Andrew G. Hughson, David-Erick Lafontant, Chelsea Caspell‐Garcia, Christopher S. Coffey, J Mollon, Samantha J. Hutten, Kalpana Merchant, Roland G. Heym
Acta Neuropathologica Communications · 2021 · ▲ 247 citations
Abstract
Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for Parkinson's disease (PD) and related synucleinopathies. They enable detection of seeding-competent alpha-synuclein aggregates in living patients and have shown high diagnostic accuracy in several PD and other synucleinopathy patient cohorts. However, there has been confusion about αSyn-SAAs for their methodology, nomenclature, and relative accuracies when performed by various laboratories. We compared αSyn-SAA results obtained from three independent laboratories to evaluate reproducibility across methodological variations. We utilized the Parkinson's Progression Markers Initiative (PPMI) cohort, with DATSCAN data available for comparison, since clinical diagnosis of early de novo PD is critical for neuroprotective trials, which often use dopamine transporter imaging to enrich their cohorts. Blinded cerebrospinal fluid (CSF) samples for a randomly selected subset of PPMI subjects (30 PD, 30 HC, and 20 SWEDD), from both baseline and year 3 collections for the PD and HC groups (140 total CSF samples) were analyzed in parallel by each lab according to their own established and optimized αSyn-SAA protocols. The αSyn-SAA results were remarkably similar across laboratories, displaying high diagnostic performance (sensitivity ranging from 86 to 96% and specificity from 93 to 100%). The assays were also concordant for samples with results that differed from clinical diagnosis, including 2 PD patients determined to be clinically inconsistent with PD at later time points. All three assays also detected 2 SWEDD subjects as αSyn-SAA positive who later developed PD with abnormal DAT-SPECT. These multi-laboratory results confirm the reproducibility and value of αSyn-SAA as diagnostic tools, illustrate reproducibility of the assay in expert hands, and suggest that αSyn-SAA has potential to provide earlier diagnosis with comparable or superior accuracy to existing methods.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s40478-021-01282-8
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Russo, M.J., Orru, C.D., Concha‐Marambio, L., Giaisi, S., Groveman, B.R., Farris, C.M., Holguin, B., Hughson, A.G., Lafontant, D., Caspell‐Garcia, C., Coffey, C.S., Mollon, J., Hutten, S.J., Merchant, K., Heym, R.G., Soto, C.A., Caughey, B.W., & Kang, U.J. (2021). High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. <em>Acta Neuropathologica Communications</em>. https://doi.org/10.1186/s40478-021-01282-8
Vancouver
Russo MJ, Orru CD, Concha‐Marambio L, Giaisi S, Groveman BR, Farris CM, et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. Acta Neuropathologica Communications. 2021. doi:10.1186/s40478-021-01282-8.
BibTeX
@article{marco2021Highdi,
title = {High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease},
author = {Marco J. Russo and Christina Doriana Orru and Luis Concha‐Marambio and Simone Giaisi and Bradley R. Groveman and Carly M. Farris and Bret Holguin and Andrew G. Hughson and David-Erick Lafontant and Chelsea Caspell‐Garcia and Christopher S. Coffey and J Mollon and Samantha J. Hutten and Kalpana Merchant and Roland G. Heym and Claudio A. Soto and Byron W. Caughey and Un Jung Kang},
journal = {Acta Neuropathologica Communications},
year = {2021},
doi = {10.1186/s40478-021-01282-8},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Movement Disorders 2019
Open access · CC-BY
Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease
Acta Neuropathologica Communications 2021
Open access · CC-BY
Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies
Frontiers in aging neuroscience 2026
Citation only
Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.
JAMA Neurology 2020
Open access · CC-BY
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
Alzheimer s Research & Therapy 2023
Open access · CC-BY
Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning
European Journal of Heart Failure 2016
Open access · OA